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Introduction
The concept of a hype cycle is a well-established business 
concept, in which novel ideas are said to have an initial wave 
of hype followed by disillusionment. Only after that, the 
novel concept takes off and become truly useful entering 
a so-called plateau of productivity. In biomedical science, 
the field of microRNAs (miRNAs) certainly had a peak 
of interest in the end of the last decade. This led by high 
impact publications (1) and characterization of both novel 
miRNA-entities as well as their associations to a broad 
range of diseases. Nonetheless, no clear pharmaceutical 
successes emerged: miRNA targets are being pursued as 
therapeutic targets, but none have as of yet successfully 
made it through clinical trials (2). Likewise the use of 
miRNA-based treatment strategies targeting regular mRNA 
is an area of interest (3). In this editorial we focus on a 
third aspect of miRNAs: the use of miRNAs as prognostic 
biomarkers in disease, asking the question if miRNAs are 
now entering this plateau of productivity in which actual 
benefit will be seen.
We focus on the recent paper by Bye et al.: “Circulating 
microRNAs predict future fatal myocardial infarction in 
healthy individuals - The HUNT study” (4). This paper is of 
particular interest because it presents strong evidence for 
prognostic benefit of miRNAs. The study was based on the 
HUNT cohort, a Norwegian biobank-initiative in which 
an impressive 88% of the adult population of the Nord-
Trøndelag County participated, giving blood samples and 
questionnaire information in 1984, 1995, and 2006. With 
the unique advantage of having both frozen serum and 
decades of follow-up information, the study was designed 
as a prospective nested case-control design with fatal 
acute myocardial infarct (AMI) as endpoint and controls 
matched on risk factors such as body mass index (BMI), 
total cholesterol and high-density lipoprotein cholesterol 
(HDL-C) (4). The main discovery phase results yielded 
12 miRNAs that were associated with future AMI. This 
editorial will discuss the perspectives of these findings as 
well as considerations for similar future miRNA studies.
The methodology of miRNA normalization
A key consideration in biomarker studies is the existence 
of similar studies. For miRNA biomarkers predicting 
AMI, several studies already exist that address AMI risk. 
Typically the main focus is the discovery of biomarkers 
for immediate use, such as distinguishing patients with 
ST-elevated AMI from patients with stable ischemic 
heart disease (5), or between ongoing AMI and healthy 
controls (6). The most comparable study to the interest 
of this editorial is the one Zampetaki et al. In this study, 
the main focus was the prediction of future AMI and the 
authors did find association of miR-126, miR-223 and miR-
197 to the disease (7). It is noteworthy that none of these 
miRNAs were identified by Bye et al. (4). Hence, for the 
overall purpose of using miRNAs as predictive biomarkers it 
prompts an important discussion on methodological choice. 
Bye et al. suggested that one main discrepancy reason 
could be the choice of data normalization method and 
the platform for miRNA analysis. In fact, while Bye et al. 
used a panel of seven reference genes for normalization 
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and quality control by means of the RNA Spike-in kit 
including cel-miR-39-3p, UniSp2, UniSp4, UniSp5 and 
UniSp6, Zampetaki et al. (7) solely used U6, which is 
not a suitable endogenous control for the quantification 
of circulating miRNAs based on previous works (8,9). It 
has been shown that the Spike-in system improves the 
quality of the normalization step (10). The normalization 
method for circulating miRNA quantification is one of the 
critical aspects in this field and from this point of view the 
normalization procedure used in the work of Bye et al. is the 
most robust to date.
Sample collection and processing in miRNA 
analysis
Another crucial aspect for the analysis of circulating 
miRNAs is the collection and processing of blood samples. 
In fact, it has been suggested that blood must be processed 
within a few hours after collection in order to prevent cell-
derived miRNA contamination from red blood cells or 
platelets (11-13). Unfortunately, many studies do not follow 
this suggestion or do not report this important information. 
Moreover, it has been shown that the difference between 
serum and plasma strongly affects the spectrum of 
circulating miRNA in blood (11) demonstrating higher 
miRNA concentrations in serum samples compared to the 
corresponding plasma samples. Considering that Bye et al. 
and Zampetaki et al. extracted miRNAs from serum and 
plasma, respectively, and that they used two different RNA 
isolation kits (miRCURY RNA isolation and miRNeasy 
kit, respectively), it is plausible that the two studies did 
not find the same miRNAs. All these considerations point 
the attention on the fact that, given the numerous factors 
that generate variability in circulating miRNA studies, it 
is now mandatory to develop standard protocols for blood 
specimen collection and processing to allow the comparison 
across studies.
Using small RNA-seq to improve the quality of 
the results
Circulating miRNAs are considered novel non-invasive 
biomarkers. Yet, the mechanism of action at the molecular 
level both in healthy and disease is still largely unknown. 
Since there is a great opportunity to establish a new 
paradigm of intercellular communication, the National 
Institutes of Health (NIH) funded a novel Common Fund’s 
Extracellular RNA Communication (ERC) program “(I) 
to discover fundamental biological principles about the 
mechanisms of extracellular RNA (exRNA) generation, 
secretion, and transport; (II) to identify and develop a 
catalogue of exRNA in normal human body fluids; (III) and 
to investigate the potential for using exRNAs as therapeutic 
molecules or biomarkers of disease”. In order to disseminate 
the knowledge derived from this program, the results are 
shared through the exRNA research portal, a community-
wide resource for exRNA standards, protocols and data. 
These efforts have already generated new small RNA-seq 
data for several conditions (including cardiovascular diseases 
and cancer), biofluids (e.g., plasma and serum) and RNA 
sources (e.g., exosomes and other extracellular vesicles). 
Since the quality, the amount and the specific body fluid are 
important factors (as discussed above), RNA-seq is likely 
to be the future standard technique in this field. Still, small 
RNA-seq is not the common method used as shown in the 
miRandola database, the circulating RNAs database (14). In 
the work of Bye et al. and in many other published studies, 
qRT-PCR has been used as golden standard for miRNA 
quantification. Since in this context the normalization step 
is crucial and there is no clear agreement in the scientific 
society, using small RNA-seq could solve this crucial 
problem, increasing the quality of the results. Overall, 
rigorous standardized methods and analyses are needed 
in this field. It has been reported that many confounding 
factors exist in the phases of processing, extraction and 
quantification of exRNAs. 
Statistical considerations in search for 
predictive biomarkers
In understanding biomarker discovery studies it is important 
to be very aware of the statistical pitfalls associated with 
them (15). The archetypical discovery study pitfall is that 
of the winner’s curse; that testing hundreds of metrics will 
inevitable yield significant findings by chance and that their 
effect estimates will be inflated (16). In the Bye et al. study (4) 
the study design was built around a discovery phase as well 
as a validation phase. In the discovery phase, 76 miRNAs 
were tested, of which 12 were selected at an uncorrected 
P<0.05 significance threshold. This alone is of course a 
clear example of test metric inflation and winner’s curse, 
and it follows that the ΔΔCq values should decrease in the 
validation phase, which in fact they do. However, the study 
also included a validation phase within which it was shown 
that ten of the 12 miRNAs were significantly associated 
with future AMI at P<0.05. No metric was provided 
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reporting with a formal multiple testing correction of 
12 miRNAs, but it is reported that four of the 12 miRNAs 
also were significant at P<0.01. Further, Bye et al. presents 
a combination signature of five other miRNAs. These 
resulted from the testing of 4,095 different combinations 
with no independent replication. It is from this signature 
that the 0.91 AUC is concluded. 
The replication and validation setup is a good strategy 
to amend winners curse problems. Ultimately, however, the 
proper question to debate here is of course whether these 
statistics will hold up in a general case. The combination 
signature score of 0.91 AUC finding was based on a large 
un-replicated multiple burden and so is highly likely to 
decrease on independent validation. However, the individual 
miRNA scores were independently replicated suggesting 
that they are true in a general case. And that is a novelty in 
a field burdened by underpowered discovery studies without 
genuine follow up, so we believe that at least the four 
strongly replicating miRNAs, let-7g-5p, miR-26a-5p, miR-
106a-5p, and miR-151a-5p, could play important future 
roles in the field of AMI prognostics. 
Conclusions
Current prediction algorithms in clinical use include the 
European Society of Cardiology’s Systematic Coronary 
Risk Evaluation (SCORE) and the Framingham risk score 
(17,18). These algorithms have some impact in a clinical 
setting; by accurately assigning patients to risk-groups they 
can prompt important discussions of smoking patterns, 
LDL-cholesterol levels and overall healthy lifestyle. 
However, the scores are still too inaccurate to clearly 
pinpoint the individuals who will in fact become future 
patients. This is the reason why predictive biomarkers are 
of such interest. Having the ability to identify individuals 
who has a high risk of adverse events with only low chance 
of false positives; that is a hallmark of precision medicine, 
and one that is not possible only with the current life-style 
based clinical scores. 
While the work with miRNA biomarkers for AMI is still 
in its infancy, studies like Bye et al. pave a way for a future in 
which life-style scores could be supplemented with simple 
and cheap blood-test-based biomarker predictions, and 
resultant in early and accurate intervention. More accurate 
intervention, importantly, also means less wasteful and non-
required treatment of individuals who are in fact not at 
risk. And this optimization of the health care system really 
is the grand perspective to have in mind when considering 
precision medicine in general, and studies like Bye et al. in 
particular.
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